These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 22404696)

  • 1. Complete immunotolerance induction after FEIBA prophylaxis in a haemophilia A patient with high-titre inhibitor.
    Nanishi E; Ohga S; Doi T; Ishimura M; Ihara K; Takada H; Shima M; Hara T
    Haemophilia; 2012 May; 18(3):e75-7. PubMed ID: 22404696
    [No Abstract]   [Full Text] [Related]  

  • 2. How I treat inhibitors in haemophilia.
    Makris M; Hay CR; Gringeri A; D'Oiron R
    Haemophilia; 2012 Jul; 18 Suppl 4():48-53. PubMed ID: 22726083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series.
    Ettingshausen CE; Kreuz W
    Haemophilia; 2010 Jan; 16(1):90-100. PubMed ID: 19878335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemophilia A and inhibitors: advances in prevention and ITI treatment optimization.
    Kruse-Jarres R
    Haemophilia; 2014 Sep; 20 Suppl 6():1. PubMed ID: 24975699
    [No Abstract]   [Full Text] [Related]  

  • 5. FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations.
    Perry D; Berntorp E; Tait C; Dolan G; Holme PA; Laffan M; Lassila R; Mumford A; Pasi J; Wilde J; Will A; Yee TT
    Haemophilia; 2010 Jan; 16(1):80-9. PubMed ID: 19780845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors.
    Ewing N; Escuriola-Ettingshausen C; Kreuz W
    Haemophilia; 2015 May; 21(3):358-364. PubMed ID: 25603840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units.
    Ter Avest PC; Fischer K; Gouw SC; Van Dijk K; Mauser-Bunschoten EP
    Haemophilia; 2010 May; 16(102):71-9. PubMed ID: 20536988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study.
    Zanon E; Milan M; Gamba G; Ambaglio C; Saggiorato G; Spiezia L; Montani N; Prandoni P
    Thromb Res; 2015 Dec; 136(6):1299-302. PubMed ID: 26505666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
    Valentino LA
    Haemophilia; 2010 Mar; 16(2):263-71. PubMed ID: 20028421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis in haemophilia patients with inhibitors.
    Leissinger CA
    Haemophilia; 2006 Dec; 12 Suppl 6():67-72; discussion 72-3. PubMed ID: 17123397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients.
    Teitel J; Berntorp E; Dolan G; Fischer K; Gringeri A; Kessler C; Lambert T; Leissinger C; Nemes L; Shima M
    Haemophilia; 2011 May; 17(3):516-21. PubMed ID: 21371181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experiences in the prevention of arthropathy in haemophila patients with inhibitors.
    Jimenez-Yuste V; Rodriguez-Merchan EC; Alvarez MT; Quintana M; Martin-Salces M; Hernandez-Navarro F
    Haemophilia; 2008 Nov; 14 Suppl 6():28-35. PubMed ID: 19134031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitor development, immune tolerance and prophylaxis in haemophilia A--the need for an evidence-based approach.
    Mannucci PM; Abshire T; Dimichele D; Santagostino E; Blanchette V
    Haemophilia; 2006 Jul; 12(4):429-34. PubMed ID: 16834746
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of FEIBA for acute bleeding and surgical haemostasis in haemophilia A patients with inhibitors: a multicentre registry in Turkey.
    Zülfikar B; Aydogan G; Salcioglu Z; Oner AF; Kavakli K; Gursel T; Zülfikar H;
    Haemophilia; 2012 May; 18(3):383-91. PubMed ID: 22103429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors in haemophilia A: current management and open issues.
    Haya S; Moret A; Cid AR; Cortina V; Casaña P; Cabrera N; Aznar JA
    Haemophilia; 2007 Dec; 13 Suppl 5():52-60. PubMed ID: 18078398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations.
    Jiménez-Yuste V; Alvarez MT; Martín-Salces M; Quintana M; Rodriguez-Merchan C; Lopez-Cabarcos C; Velasco F; Hernández-Navarro F
    Haemophilia; 2009 Jan; 15(1):203-9. PubMed ID: 19149850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective.
    Oldenburg J; Austin SK; Kessler CM
    Haemophilia; 2014 Sep; 20 Suppl 6():17-26. PubMed ID: 24975701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-emergence of a low-titre factor VIII inhibitor after liver transplant.
    Horton S; Martlew V; Wilde J; Thachil J
    Haemophilia; 2012 May; 18(3):e69-71. PubMed ID: 22531024
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of factor VIII inhibitors in two patients with moderate haemophilia A.
    Paschal RD; Meeks SL; Neff AT
    Haemophilia; 2013 Jan; 19(1):e55-7. PubMed ID: 23171275
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibitor development in patients with hemophilia: an overview.
    Leissinger CA
    Semin Hematol; 2006 Apr; 43(2 Suppl 4):S1-2. PubMed ID: 16690370
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.